INDIA MUCORMYCOSIS TREATMENT (BLACK FUNGUS DRUGS) MARKET ANALYSIS

India Mucormycosis Treatment (Black Fungus Drugs) MarketSize and Trends

India Mucormycosis Treatment (Black Fungus Drugs) Market is estimated to be valued at US$ 9.1 Mn in 2021 and is expected to exhibit a CAGR of 3.5% over the forecast period (2021-2028).

 Figure 1: India Mucormycosis Treatment (Black Fungus Drugs) Market Share (%) Analysis, By Species, 2021

Market Players are engaged in receiving license from the Indian government, in order to manufacture Amphotericin – B, an anti-fungal drug for the treatment of Black Fungus or mucormycosis. This is expected to drive growth of the India Mucormycosis Treatment (Black Fungus Drugs) market over the forecast period.

Indian government has provided license to some of the market players, in order to manufacture anti-fungal drug, Amphotericin – B for the treatment of Mucormycosis (Black Fungus Drugs). For instance, on May 22, 2021, Indian government gave license to five manufacturers: Emcure Pharmaceuticals, Natco Pharmaceuticals, Gufic Biosciences, Alembic Pharmaceuticals, and Lyca Pharmaceuticals. These companies will start producing 111,000 vials of Amphotericin – B each month from July 2021.

Key players are engaged in entering into an agreement, in order to manufacture anti- fungal drugs for black fungus. This is expected to drive growth of the India Mucormycosis Treatment (Black Fungus Drugs) market over the forecast period.

The increasing agreements by the market players for the manufacture of anti-fungal drug in the treatment of mucormycosis is expected to drive growth of the market over the forecast period. For instance, on May 26, 2021, Cadila Healthcare Limited and TLC Pharma Labs, entered into an agreement to manufacture anti-fungal drug ‘Liposomal Amphotericin B’ for the treatment of mucormycosis or black fungus in India.

Increasing prevalence of mucormycosis in the Indian population with comorbidities is expected to drive growth of the India Mucormycosis Treatment (Black Fungus Drugs) market

In India, diabetes mellitus is the most common underlying disease. For instance, according to the article published in the Microorganism Journal, on March 4, 2021, the pie chart shows the percentage of mucormycosis burden in different at-risk populations in India. According to the same source, diabetes mellitus is a common predisposing factor for the rhino-orbital-cerebral mucormycosis (ROCM) type of disease. A recent study from India reported that 77% of ROCM cases were in the diabetic population.

Moreover, according to the article published by the Indian Ministry of Chemicals and Fertilizers, around 8,848 cases of mucormycosis has been reported till May 25, 2021 in India. The following graph shows the number of cases of mucormycosis infection reported in each state in India, till May 25, 2021.

India Mucormycosis Treatment (Black Fungus Drugs) Market Report Coverage